Neuland Laboratories Ltd. plans to open a commercial‑scale peptide manufacturing facility in summer 2026 at its 17‑acre Bonthapally campus in Hyderabad, expanding its capacity amid rising global demand for complex peptides, including GLP‑1 drugs.

The first of four planned manufacturing modules is slated to come online this summer. Neuland said that module has secured firm commitments of approximately $30 million, which will add 6,370 liters of solid‑ and liquid‑phase peptide synthesis capacity. Equipment in the first unit will include LPPS reactors ranging from 250 to 3,000 liters and SPPS reactors up to 500 liters.

Construction began last year. The facility is designed to support volumes from early development through multi‑ton commercial production, with flexibility for long‑chain and other complex peptide programs. The company said the site will be built for incremental expansion, with space for additional 2,000‑liter SPPS units and multiple 5,000‑liter LPPS reactors in later modules.

Neuland aims to attract innovator and emerging biotechnology companies facing tightening access to peptide manufacturing capacity, particularly as GLP‑1 therapies occupy a growing share of global production resources.

The company expects double‑digit growth in R&D staffing this year and plans to more than double its manufacturing team to support the peptide build‑out. Neuland currently operates three FDA‑approved API plants with a combined 1.17 million liters of capacity, supported by a dedicated R&D center nearby.

The new peptide facility will incorporate digital operations and DCS‑based automation with electronic batch‑record systems. It will also include scaled‑up purification and drying capabilities—such as multi‑column prep‑HPLC, large lyophilizers, expanded solvent‑handling infrastructure, and upgraded waste‑management systems—aimed at improving batch consistency and cycle times.

“Building on the strength of our reputation among innovator and biotech customers for complex API capabilities, this new facility marks our strategic entry into commercial-scale peptide manufacturing,” said Saharsh Davuluri, Vice Chairman and MD at Neuland Labs. “A key part of our strategy will be to first support innovator and emerging biotech companies across all areas of novel peptide development, as well as the ongoing demand for GLP-1 manufacturing. We see commercial peptide production as a key growth driver for the business over the coming years. So, we are now scaling rapidly and expect to rollout all modules of the new peptide facility in line with customer demand.”